Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifidobacterium triple viable capsules for allergic rhinitis
ChiCTR2100052510Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jan 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bifidobacterium triple viable in allergic rhinitis (AR) (2 arms), sponsored by Tongji Hospital. Primary endpoint: Total Nasal Symptom Score and Total Ocular Symptom Score. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
bifidobacterium triple viable
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on ChiCTR2100052510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052510.